A merger between top pharma suppliers like West Pharma and Stevanato is improbable. Drug manufacturers deliberately "spec in" two or three different suppliers for a single drug to de-risk their supply chains. A merger would eliminate this critical redundancy, facing strong opposition from both customers and regulators.

Unlike small-molecule drugs, biologics manufacturing cannot be simply scaled up on demand because "the process is the product." A superior manufacturing and supply chain capability is not a back-office function but a key market differentiator that commercial teams must leverage to win customers and outpace competitors.

Ipsen's billion-dollar drug Somatoline is maintaining strong sales despite facing generic competition since 2021. The drug is extremely difficult to manufacture, which has prevented generic players from ramping up production. This "manufacturing moat" serves as a powerful, often overlooked, defense against revenue erosion after a patent cliff.

Adderall's success proves a core chemical patent isn't essential for market dominance. A strong brand that becomes synonymous with a condition, combined with secondary patents on novel delivery mechanisms (like Adderall XR's capsule), can create a durable, highly profitable business moat.

Rather than selling single products, Novonesis designs custom blends or "cocktails" of different enzymes and microbes. This tailor-made approach solves specific customer problems so effectively that it makes the solution highly unique and difficult for competitors to replicate.

While patents are important, a pharmaceutical giant's most durable competitive advantage is its ability to navigate complex global regulatory systems. This 'regulatory know-how' is a massive barrier to entry that startups cannot easily replicate, forcing them into acquisition by incumbents.

Palvela targets a market inefficiency by taking dermatology drugs typically sourced from compounding pharmacies for orphan diseases and developing them into proprietary, FDA-approved products. This strategy creates a regulated, reliable supply chain for rare conditions while building a valuable commercial franchise.

Once a TransDigm part is certified for a specific aircraft model, it cannot be substituted for the plane's entire 30-50 year lifespan. This regulatory lock-in creates hundreds of mini-monopolies, giving TransDigm immense and durable pricing power on replacement parts.

Following the playbook of healthcare software giant Epic Systems, the most durable competitive moat in GovTech is to have your product's specific features and requirements written directly into state or federal law. This tactic makes your company an essential, legally-mandated vendor, effectively locking out competitors.